{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:28:12Z","timestamp":1792182492554,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00520-016-3299-7","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T13:53:34Z","timestamp":1465566814000},"page":"4577-4586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcome prognostic factors in inoperable malignant bowel obstruction"],"prefix":"10.1007","volume":"24","author":[{"given":"Margarita","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de los LLanos Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Cuadra Urteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ahlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Indacochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Radua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"3299_CR1","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jpainsymman.2007.04.011","volume":"34","author":"T Anthony","year":"2007","unstructured":"Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, Herbst A, Smart E, Krouse RS (2007) Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manag 34:S49\u2013S59","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CMAR.S29297","volume":"4","author":"A Tuca","year":"2012","unstructured":"Tuca A, Guell E, Martinez-Losada E, Codorniu N (2012) Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 4:159\u2013169","journal-title":"Cancer Manag Res"},{"key":"3299_CR3","unstructured":"Feuer DJ, Broadley K. (2004) Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. In: The Cochrane Library. Wiley, Chichester"},{"key":"3299_CR4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpainsymman.2004.01.007","volume":"28","author":"S Mercadante","year":"2004","unstructured":"Mercadante S, Ferrera P, Villari P, Marrazzo A (2004) Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manag 28:412\u2013416","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR5","first-page":"20","volume":"1","author":"MT Fallon","year":"1994","unstructured":"Fallon MT (1994) The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care 1:20\u201322","journal-title":"Eur J Palliat Care"},{"key":"3299_CR6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s005200050283","volume":"8","author":"S Mercadante","year":"2000","unstructured":"Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188\u2013191","journal-title":"Support Care Cancer"},{"key":"3299_CR7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12957-015-0455-3","volume":"13","author":"X Peng","year":"2015","unstructured":"Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol 13:50","journal-title":"World J Surg Oncol"},{"key":"3299_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","volume":"19","author":"C Ripamonti","year":"2000","unstructured":"Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manag 19:23\u201334","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR9","first-page":"1187","volume":"22","author":"K Mystakidou","year":"2002","unstructured":"Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L (2002) Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 22:1187\u20131192","journal-title":"Anticancer Res"},{"key":"3299_CR10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.critrevonc.2011.12.006","volume":"83","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G (2012) Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 83:388\u2013392","journal-title":"Crit Rev Oncol Hematol"},{"key":"3299_CR11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0885-3924(91)90005-O","volume":"6","author":"F Conno De","year":"1991","unstructured":"De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manag 6:484\u2013486","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.2011.597382","volume":"12","author":"B O\u2019Connor","year":"2011","unstructured":"O\u2019Connor B, Creedon B (2011) Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother 12:2205\u20132214","journal-title":"Expert Opin Pharmacother"},{"key":"3299_CR13","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1200\/JCO.2011.40.5712","volume":"30","author":"P Mariani","year":"2012","unstructured":"Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30:4337\u20134343","journal-title":"J Clin Oncol"},{"key":"3299_CR14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0885-3924(98)00101-8","volume":"16","author":"S Mercadante","year":"1998","unstructured":"Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manag 16:278\u2013280","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jpainsymman.2005.10.009","volume":"31","author":"G Laval","year":"2006","unstructured":"Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N (2006) Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manag 31:502\u2013512","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","volume":"49","author":"DC Currow","year":"2015","unstructured":"Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag 49:814\u2013821","journal-title":"J Pain Symptom Manag"},{"key":"3299_CR17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00520-010-1009-4","volume":"19","author":"G Porzio","year":"2011","unstructured":"Porzio G, Aielli F, Verna L, Galletti B, Shoja ERG, Ficorella C (2011) Can malignant bowel obstruction in advanced cancer patients be treated at home? Support Care Cancer 19:431\u2013433","journal-title":"Support Care Cancer"},{"key":"3299_CR18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jjco\/hyq048","volume":"40","author":"T Hisanaga","year":"2010","unstructured":"Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I (2010) Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 40:739\u2013745","journal-title":"Jpn J Clin Oncol"},{"key":"3299_CR19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.medcli.2010.03.002","volume":"135","author":"A Tuca","year":"2010","unstructured":"Tuca A, Martinez E, Guell E, Gomez Batiste X (2010) Malignant bowel obstruction. Med Clin (Barc) 135:375\u2013381","journal-title":"Med Clin (Barc)"},{"key":"3299_CR20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/IGC.0b013e318244ce93","volume":"22","author":"H Watari","year":"2012","unstructured":"Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N (2012) A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Int J Gynecol Cancer 22:692\u2013696","journal-title":"Int J Gynecol Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3299-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:06:43Z","timestamp":1498320403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3299-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]}}}